\-\ Texto\\:\\ \ \(0\)\
\-\ external\\ examination\\:\\ bilateral\\ superotemporal\\ firm\\,\\ non\\-mobile\\ subconjunctival\\ masses\\ with\\ dilated\\ vasculature\\;\\ 3\\.5\\ mm\\ right\\ proptosis\\;\\ full\\ ductions\\,\\ no\\ diplopia\ \(0\)\
\-\ internal\\ examination\\:\\ 2\\-3\\+\\ nuclear\\ sclerotic\\ cataracts\\ o\\.u\\.\\ resulting\\ in\\ 20\\/40\\ \\â\\€\\“\\ 20\\/50\\ best\\ corrected\\ va\\;\\ choroidal\\ nevus\\,\\ unchanged\\ for\\ 15\\ years\ \(0\)\
\-\ may\\ 2004\\:\ \(0\)\
\-\ rx\\:\\ thalidomide\ \(0\)\
\-\ shrinkage\\ of\\ orbital\\ masses\ \(0\)\
\-\ march\\ 2005\\:\ \(0\)\
\-\ clinical\\ examination\\:\\ recurrence\\ right\\ orbit\ \(0\)\
\-\ rx\\:\\ liposomal\\ vincristine\ \(0\)\
\-\ november\\ 2005\\:\ \(0\)\
\-\ no\\ evidence\\ of\\ orbital\\ disease\ \(0\)\
\-\ biopsies\\ of\\ right\\ orbital\\ lobe\\ of\\ lacrimal\\ gland\\ and\\ right\\ subconjunctival\\ mass\\.\ \(0\)\
\-\ histopathology\\:\\ monomorphous\\ centrocyte\\-like\\ small\\ lymphocytes\\,\\ cyclin\\ d1\\ \\+\\ \\[ihc\\]\ \(0\)\
\-\ flow\\ cytometry\\:\\ cd5\\/cd20\\ \\+\\,cd10\\,\\ cd23\\ \\â\\€\\“\\,\\ fmc7\\ \\+\ \(0\)\
\-\ cytogenetics\\:\\ t\\(11\\;14\\)\\(q12\\-13\\.1\\;q32\\)\ \(0\)\
\-\ mantle\\ cell\\ lymphoma\ \(1\)\
\-\ 70\\-year\\-old\\ female\\ with\\ \\â\\€\\˜swollen\\ eyelids\\â\\€\\™\\ and\\ pain\\ on\\ abduction\\ of\\ right\\ eye\\ x\\ 4\\ days\\.\ \(1\)\
\-\ remote\\ history\\ of\\ breast\\ \\(age\\ 46\\)\\ and\\ ovarian\\ \\(age\\ 28\\)\\ cancer\\.\ \(0\)\
\-\ 1999\\:\\ mantle\\ cell\\ lymphoma\\,\\ periaortic\\ lymph\\ nodes\\/ileocecal\\ valve\\/bone\\ marrow\\:\\ chop\\,\\ hyper\\ cvad\\.\\ autologous\\ stem\\ cell\\ transplant\\ 2002\\.\\ no\\ chemotherapy\\ since\\ january\\ 2004\ \(0\)\
\-\ recently\\ defined\\ category\\ of\\ b\\-cell\\ lymphomas\\ \\(3\\-10\\%\\)\\.\ \(0\)\
\-\ clinical\\ features\\:\ \(0\)\
\-\ late\\ adulthood\\ \\(median\\ age\\ 60\\)\ \(0\)\
\-\ male\\ predominance\ \(11\)\
\-\ multifocal\\ lymphadenopathy\\,\\ hepatosplenomegaly\\,\\ bone\\ marrow\\ involvement\ \(0\)\
\-\ gi\\ tract\\,\\ waldeyer\\â\\€\\™s\\ ring\\ also\\ common\\ extranodal\\ sites\ \(0\)\
\-\ median\\ survival\\ 3\\-5\\ years\ \(0\)\
\-\ cell\\ of\\ origin\\:\\ \\â\\€\\˜mantle\\ cell\\â\\€\\™\\ immediately\\ surrounding\\ follicle\\:\ \(0\)\
\-\ \\â\\€\\˜centrocyte\\-like\\â\\€\\™\\ morphology\ \(0\)\
\-\ proliferative\\ in\\ monotonous\\ sheets\\ of\\ small\\ cells\\ with\\ irregular\\ nuclear\\ contours\\,\\ inconspicuous\\ nucleoli\ \(0\)\
\-\ hyalinized\\ capillaries\ \(0\)\
\-\ immunophenotype\\:\ \(0\)\
\-\ b\\-cell\\ lymphocyte\ \(0\)\
\-\ cd19\\+\\,\\ cd20\\+\ \(0\)\
\-\ coexpression\\ of\\ cd5\\ \\(cd5\\+\\/cd20\\+\\)\ \(0\)\
\-\ ddx\\:\\ sll\\/cll\ \(0\)\
\-\ negative\\ for\\:\ \(0\)\
\-\ cd23\\ \\(cll\\/sll\\ cd5\\+\\,cd23\\+\\)\ \(0\)\
\-\ cd10\\ \\(fl\\ cd5\\-\\,cd10\\+\\)\\;\\ \\(malt\\ cd5\\-\\,cd10\\-\\)\ \(0\)\
\-\ cyclin\\ d1\\+\\,\\ fmc7\\+\ \(0\)\
\-\ cytogenetics\\:\ \(0\)\
\-\ t\\(11\\;14\\)\\ \\(q13\\;q32\\)\ \(1\)\
\-\ juxtaposition\\ of\\ ig\\ heavy\\ chain\\ promoter\\ and\\ cyclin\\ d1\\ gene\ \(0\)\
\-\ overexpression\\ of\\ cyclin\\ d1\\ gene\\,\\ increased\\ mrna\\,\\ gene\\ product\ \(0\)\
\-\ promotes\\ phosphorylation\\ of\\ prb\\,\\ passage\\ of\\ cell\\ into\\ s\\ phase\ \(0\)\
\-\ ocular\\ adnexal\\ involvement\\:\ \(0\)\
\-\ rare\\:\\ eyelid\\,\\ conjunctiva\\,\\ orbit\\,\\ lacrimal\\ gland\ \(0\)\
\-\ 3\\-5\\%\\ of\\ all\\ ocular\\ adnexal\\ lymphomas\ \(1\)\
\-\ demographics\ \(7\)\
\-\ age\\ \\>\\ 60\ \(0\)\
\-\ m\\ \\>\\>\\ f\ \(0\)\
\-\ aggressive\\ behavior\ \(0\)\
\-\ median\\ survival\\ \\<\\ 5\\ years\ \(0\)\
\-\ largest\\ series\\:\\ white\\,\\ rootman\\ et\\ al\ \(0\)\
\-\ 10\\ cases\\:\\ \ \(1\)\
\-\ 9\\ with\\ multiple\\ periocular\\ sites\ \(1\)\
\-\ 6\\ bilateral\ \(1\)\
\-\ 9\\ orbital\\,\\ 5\\ lacrimal\\ gland\\,\\ 5\\ eyelid\ \(1\)\
\-\ 8\\ periocular\\ presenting\\ site\ \(1\)\
\-\ unusual\\ findings\ \(1\)\
\-\ 3\\ cases\\ cd5\\ \\â\\€\\“\ \(0\)\
\-\ 2\\ cases\\ composite\\ lymphomas\ \(1\)\
\-\ mantle\\ cell\\/follicular\\ lymphoma\ \(0\)\
\-\ mantle\\ cell\\/plasma\\ cell\\ neoplasm\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ cd5\\:\\ 0\\.36507626176644087\ \(0\)\
\-\ mantle\\:\\ 0\\.24209070293632032\ \(0\)\
\-\ cyclin\\:\\ 0\\.2319085315849382\ \(0\)\
\-\ cell\\:\\ 0\\.22812497802992945\ \(0\)\
\-\ d1\\:\\ 0\\.2216009826296278\ \(0\)\
\-\ cd10\\:\\ 0\\.20006136306428393\ \(0\)\
\-\ cd23\\:\\ 0\\.16620073697222087\ \(0\)\
\-\ lymphomas\\:\\ 0\\.14142840262473888\ \(0\)\
\-\ lacrimal\\:\\ 0\\.12909970708778432\ \(0\)\
\-\ gene\\:\\ 0\\.1273652248130043\ \(0\)\
\-\ orbital\\:\\ 0\\.127196248137858\ \(0\)\
\-\ subconjunctival\\:\\ 0\\.1159542657924691\ \(0\)\
\-\ fmc7\\:\\ 0\\.1159542657924691\ \(0\)\
\-\ q32\\:\\ 0\\.1159542657924691\ \(0\)\
\-\ periocular\\:\\ 0\\.1159542657924691\ \(0\)\
\-\ median\\:\\ 0\\.11255980440892546\ \(0\)\
\-\ cytogenetics\\:\\ 0\\.1108004913148139\ \(0\)\
\-\ of\\:\\ 0\\.10641954767283547\ \(0\)\
\-\ rx\\:\\ 0\\.09216221539497488\ \(0\)\
\-\ age\\:\\ 0\\.09104105834538961\ \(0\)\
\-\ eyelid\\:\\ 0\\.08875237306887052\ \(0\)\
\-\ gland\\:\\ 0\\.08835034954589091\ \(0\)\
\-\ ocular\\:\\ 0\\.07429922680950511\ \(0\)\
\-\ cases\\:\\ 0\\.07315267297304533\ \(0\)\
\-\ adnexal\\:\\ 0\\.07230563793976395\ \(0\)\
\-\ sites\\:\\ 0\\.07076304777625202\ \(0\)\
\-\ survival\\:\\ 0\\.07076304777625202\ \(0\)\
\-\ examination\\:\\ 0\\.06959622273097761\ \(0\)\
\-\ 2005\\:\\ 0\\.06890786089395663\ \(0\)\
\-\ nuclear\\:\\ 0\\.0685978266984848\ \(0\)\
\-\ 2004\\:\\ 0\\.0682951749756111\ \(0\)\
\-\ orbit\\:\\ 0\\.06715186346210873\ \(0\)\
\-\ years\\:\\ 0\\.06666860925930976\ \(0\)\
\-\ lymphoma\\:\\ 0\\.06477349376681323\ \(0\)\
\-\ marrow\\:\\ 0\\.060255325048687546\ \(0\)\
\-\ right\\:\\ 0\\.06009756645350254\ \(0\)\
\-\ superotemporal\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ ductions\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ ihc\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ cvad\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ waldeyer\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ monotonous\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ immunophenotype\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ coexpression\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ q13\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ mrna\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ phosphorylation\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ prb\\:\\ 0\\.05797713289623455\ \(0\)\
\-\ thalidomide\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ liposomal\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ juxtaposition\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ promoter\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ overexpression\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ promotes\\:\\ 0\\.05540024565740695\ \(0\)\
\-\ 11\\:\\ 0\\.054281216154055345\ \(0\)\
\-\ 60\\:\\ 0\\.054231661425251376\ \(0\)\
\-\ 14\\:\\ 0\\.05413312781679397\ \(0\)\
\-\ shrinkage\\:\\ 0\\.05357191506491928\ \(0\)\
\-\ monomorphous\\:\\ 0\\.05357191506491928\ \(0\)\
\-\ extranodal\\:\\ 0\\.05357191506491928\ \(0\)\
\-\ rootman\\:\\ 0\\.05357191506491928\ \(0\)\
\-\ composite\\:\\ 0\\.05357191506491928\ \(0\)\
\-\ involvement\\:\\ 0\\.05247885524921701\ \(0\)\
\-\ cataracts\\:\\ 0\\.052153751680920124\ \(0\)\
\-\ follicle\\:\\ 0\\.052153751680920124\ \(0\)\
\-\ inconspicuous\\:\\ 0\\.052153751680920124\ \(0\)\
\-\ malt\\:\\ 0\\.052153751680920124\ \(0\)\
\-\ hyalinized\\:\\ 0\\.05099502782609168\ \(0\)\
\-\ sheets\\:\\ 0\\.05001534076607098\ \(0\)\
\-\ ig\\:\\ 0\\.05001534076607098\ \(0\)\
\-\ masses\\:\\ 0\\.04936128638712151\ \(0\)\
\-\ cytometry\\:\\ 0\\.04916669723360402\ \(0\)\
\-\ periaortic\\:\\ 0\\.04841814058726407\ \(0\)\
\-\ chop\\:\\ 0\\.04841814058726407\ \(0\)\
\-\ nucleoli\\:\\ 0\\.04841814058726407\ \(0\)\
\-\ eyelids\\:\\ 0\\.047748533849604854\ \(0\)\
\-\ fl\\:\\ 0\\.047748533849604854\ \(0\)\
\-\ capillaries\\:\\ 0\\.04714280087491296\ \(0\)\
\-\ lymphocyte\\:\\ 0\\.04658980999477641\ \(0\)\
\-\ conjunctiva\\:\\ 0\\.04658980999477641\ \(0\)\
\-\ va\\:\\ 0\\.04608110769748744\ \(0\)\
\-\ autologous\\:\\ 0\\.04608110769748744\ \(0\)\
\-\ clinical\\:\\ 0\\.04595144406101715\ \(0\)\
\-\ proliferative\\:\\ 0\\.04561012293475571\ \(0\)\
\-\ demographics\\:\\ 0\\.045171646610777244\ \(0\)\
\-\ behavior\\:\\ 0\\.045171646610777244\ \(0\)\
\-\ november\\:\\ 0\\.04437618653443526\ \(0\)\
\-\ choroidal\\:\\ 0\\.0440129227559488\ \(0\)\
\-\ corrected\\:\\ 0\\.04366930469919341\ \(0\)\
\-\ contours\\:\\ 0\\.04366930469919341\ \(0\)\
\-\ nevus\\:\\ 0\\.043343316018289585\ \(0\)\
\-\ product\\:\\ 0\\.043343316018289585\ \(0\)\
\-\ january\\:\\ 0\\.0430332356959281\ \(0\)\
\-\ vincristine\\:\\ 0\\.04273758304359769\ \(0\)\
\-\ adulthood\\:\\ 0\\.0424550749376681\ \(0\)\
\-\ chain\\:\\ 0\\.0424550749376681\ \(0\)\
\-\ 10\\:\\ 0\\.042398333524823986\ \(0\)\
\-\ hepatosplenomegaly\\:\\ 0\\.041925152634290426\ \(0\)\
\-\ category\\:\\ 0\\.04167588986617217\ \(0\)\
\-\ march\\:\\ 0\\.041204905103440444\ \(0\)\
\-\ biopsies\\:\\ 0\\.041204905103440444\ \(0\)\
\-\ heavy\\:\\ 0\\.041204905103440444\ \(0\)\
\-\ lymphocytes\\:\\ 0\\.040766428779461975\ \(0\)\
\-\ abduction\\:\\ 0\\.040766428779461975\ \(0\)\
\-\ unchanged\\:\\ 0\\.04035626157097348\ \(0\)\
\-\ predominance\\:\\ 0\\.04016069580477008\ \(0\)\
\-\ passage\\:\\ 0\\.03997096870311999\ \(0\)\
\-\ bone\\:\\ 0\\.03956200675682566\ \(0\)\
\-\ hyper\\:\\ 0\\.039264086867878134\ \(0\)\
\-\ bilateral\\:\\ 0\\.03896786612495287\ \(0\)\
\-\ morphology\\:\\ 0\\.03862801786461283\ \(0\)\
\-\ stem\\:\\ 0\\.03833236521228242\ \(0\)\
\-\ diplopia\\:\\ 0\\.03791317687251449\ \(0\)\
\-\ remote\\:\\ 0\\.03751993480297515\ \(0\)\
\-\ small\\:\\ 0\\.03740148414946219\ \(0\)\
\-\ largest\\:\\ 0\\.036914201828283255\ \(0\)\
\-\ proptosis\\:\\ 0\\.03657666839230787\ \(0\)\
\-\ histopathology\\:\\ 0\\.03657666839230787\ \(0\)\
\-\ 1999\\:\\ 0\\.03646802667123821\ \(0\)\
\-\ transplant\\:\\ 0\\.03625616085527055\ \(0\)\
\-\ vasculature\\:\\ 0\\.035659906459396436\ \(0\)\
\-\ no\\:\\ 0\\.03536761237274513\ \(0\)\
\-\ multifocal\\:\\ 0\\.03520248709331826\ \(0\)\
\-\ swollen\\:\\ 0\\.03502835603856056\ \(0\)\
\-\ ddx\\:\\ 0\\.034453930446978316\ \(0\)\
\-\ late\\:\\ 0\\.03422280003329756\ \(0\)\
\-\ 46\\:\\ 0\\.03330829699002045\ \(0\)\
\-\ series\\:\\ 0\\.03324311297327686\ \(0\)\
\-\ immediately\\:\\ 0\\.0331785907346272\ \(0\)\
\-\ firm\\:\\ 0\\.03286545420354162\ \(0\)\
\-\ unusual\\:\\ 0\\.032508983996967986\ \(0\)\
\-\ recently\\:\\ 0\\.03164591279446995\ \(0\)\
\-\ aggressive\\:\\ 0\\.03135026014213954\ \(0\)\
\-\ origin\\:\\ 0\\.03120743647049149\ \(0\)\
\-\ phase\\:\\ 0\\.031021864573905576\ \(0\)\
\-\ ovarian\\:\\ 0\\.030886157227312815\ \(0\)\
\-\ ring\\:\\ 0\\.030537829732832273\ \(0\)\
\-\ gi\\:\\ 0\\.030453651205247595\ \(0\)\
\-\ sclerotic\\:\\ 0\\.030411976394149498\ \(0\)\
\-\ tract\\:\\ 0\\.03037057308211884\ \(0\)\
\-\ resulting\\:\\ 0\\.030167508334609676\ \(0\)\
\-\ 28\\:\\ 0\\.03008806497618924\ \(0\)\
\-\ and\\:\\ 0\\.029965312907236485\ \(0\)\
\-\ recurrence\\:\\ 0\\.029932096758140382\ \(0\)\
\-\ external\\:\\ 0\\.029308879904693316\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.029308879904693316\ \(0\)\
\-\ site\\:\\ 0\\.029239421443722283\ \(0\)\
\-\ best\\:\\ 0\\.029170713899739097\ \(0\)\
\-\ features\\:\\ 0\\.029170713899739097\ \(0\)\
\-\ eye\\:\\ 0\\.029002126138764375\ \(0\)\
\-\ al\\:\\ 0\\.028805552141271604\ \(0\)\
\-\ et\\:\\ 0\\.028399418817983132\ \(0\)\
\-\ presenting\\:\\ 0\\.028399418817983132\ \(0\)\
\-\ with\\:\\ 0\\.02839550222058976\ \(0\)\
\-\ full\\:\\ 0\\.02833917774212202\ \(0\)\
\-\ lymph\\:\\ 0\\.0281910268397184\ \(0\)\
\-\ irregular\\:\\ 0\\.027989251609494628\ \(0\)\
\-\ cells\\:\\ 0\\.027932758918241898\ \(0\)\
\-\ rare\\:\\ 0\\.027368061669131017\ \(0\)\
\-\ breast\\:\\ 0\\.026326191919877572\ \(0\)\
\-\ since\\:\\ 0\\.026261007903133984\ \(0\)\
\-\ dilated\\:\\ 0\\.02596535525080357\ \(0\)\
\-\ mm\\:\\ 0\\.025944754305960483\ \(0\)\
\-\ defined\\:\\ 0\\.025863011881102602\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.02574233637098628\ \(0\)\
\-\ neoplasm\\:\\ 0\\.024748434619467706\ \(0\)\
\-\ 15\\:\\ 0\\.02449786132738991\ \(0\)\
\-\ internal\\:\\ 0\\.02443267731064632\ \(0\)\
\-\ surrounding\\:\\ 0\\.02417842797034657\ \(0\)\
\-\ flow\\:\\ 0\\.024147350226662402\ \(0\)\
\-\ cancer\\:\\ 0\\.024147350226662402\ \(0\)\
\-\ white\\:\\ 0\\.02391898844117585\ \(0\)\
\-\ days\\:\\ 0\\.0229499916879975\ \(0\)\
\-\ negative\\:\\ 0\\.022444252965450627\ \(0\)\
\-\ for\\:\\ 0\\.021976275047416508\ \(0\)\
\-\ all\\:\\ 0\\.021580805359391865\ \(0\)\
\-\ lobe\\:\\ 0\\.020950653848099018\ \(0\)\
\-\ evidence\\:\\ 0\\.020577503275751786\ \(0\)\
\-\ common\\:\\ 0\\.020559849414624513\ \(0\)\
\-\ increased\\:\\ 0\\.0196041330693664\ \(0\)\
\-\ into\\:\\ 0\\.019271701261773758\ \(0\)\
\-\ may\\:\\ 0\\.01824387098850654\ \(0\)\
\-\ in\\:\\ 0\\.018037355467428563\ \(0\)\
\-\ findings\\:\\ 0\\.017892523668506854\ \(0\)\
\-\ multiple\\:\\ 0\\.017732343447374965\ \(0\)\
\-\ female\\:\\ 0\\.01749395388279732\ \(0\)\
\-\ also\\:\\ 0\\.017052576218472063\ \(0\)\
\-\ male\\:\\ 0\\.016141423294690982\ \(0\)\
\-\ disease\\:\\ 0\\.015217903557880746\ \(0\)\
\-\ history\\:\\ 0\\.013850910414451174\ \(0\)\
\-\ mass\\:\\ 0\\.013847843883188167\ \(0\)\
\-\ pain\\:\\ 0\\.012972812755065281\ \(0\)\
\-\ on\\:\\ 0\\.01094915926034885\ \(0\)\
